<DOC>
	<DOCNO>NCT01837082</DOCNO>
	<brief_summary>The hypothesis test whether treatment intravenous iron ( ferric carboxymaltose ) improve left-ventricular ejection fraction patient heart failure iron deficiency determine cardiac magnetic resonance imaging .</brief_summary>
	<brief_title>Iron Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Congestive heart failure At least 18 year age Iron deficiency Dyspnea class II III accord New York Heart Association Leftventricular ejection fraction â‰¤ 45 % Known sensitivity product administer dose Immediate need transfusion Patients present active infection Thalassaemia Other form microcytic anemia cause iron deficiency History acquire iron overload Need revascularization , STsegment elevation myocardial infarction NonSTsegment elevation myocardial infarction past 3 month ( time randomization ) Women pregnant childbearing age use medically acceptable effective contraception</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Iron Deficiency</keyword>
	<keyword>Anemia</keyword>
	<keyword>Ferric Carboxymaltose</keyword>
</DOC>